Amakem Seals $25.3M Series A

Forbion Capital Partners has led an 18 million euro ($25.3 million) Series A round for Belgium-based Amakem NV. Crédit Agricole Private Equity, Vesalius BioCapital, as well as the existing investors LRM, PMV and Life Sciences Research Partners also contributed to the round. Amakem will use the money to expand its ophthalmology drug development portfolio, the company said.

North AmericaUSBriefs